(Q52888129)

9 May 2018

title

Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. (English)

1 reference

9 May 2018

1 reference

K Budde

1

1 reference

9 May 2018

F Lehner

2

1 reference

9 May 2018

C Sommerer

3

1 reference

9 May 2018

W Arns

4

1 reference

9 May 2018

P Reinke

5

1 reference

9 May 2018

U Eisenberger

6

1 reference

9 May 2018

R P Wüthrich

7

1 reference

9 May 2018

S Scheidl

8

1 reference

9 May 2018

C May

9

1 reference

9 May 2018

E-M Paulus

10

1 reference

9 May 2018

A Mühlfeld

11

1 reference

9 May 2018

H H Wolters

12

1 reference

9 May 2018

K Pressmar

13

1 reference

9 May 2018

R Stahl

14

1 reference

9 May 2018

O Witzke

15

1 reference

9 May 2018

ZEUS Study Investigators

16

1 reference

9 May 2018

language of work or name

English

0 references

publication date

5 March 2012

1 reference

9 May 2018

American Journal of Transplantation

published in

1 reference

9 May 2018

volume

12

1 reference

9 May 2018

issue

6

1 reference

9 May 2018

page(s)

1528-1540

1 reference

9 May 2018

Impact of cyclosporine on the development of immunosuppressive therapy.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Assessing glomerular filtration rate by estimation equations in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF-Four-Year Results of the Postconcept Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.03994.X

10.1111/J.1600-6143.2012.03994.X

21 January 2018

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018